Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joy of Love recall

This article was originally published in The Tan Sheet

Executive Summary

Jen-on Herbal Science International announces April 17 a voluntary nationwide recall of Joy of Love supplement product sold in 12-capsule blister packs packaged in a retail box. The City of Industry, Calif.-based firm recalled the product, marketed as a dietary supplement, after FDA investigators found the product is made with an ingredient close in structure to erectile dysfunction drug, vardenafil (Schering and GlaxoSmithKline's Levitra). Vardenafil may present an additional risk if used in combination with medications such as nitrates, which are found in certain Rx drugs used to treat conditions such as high blood pressure or heart disease. FDA ramped up surveillance of supplements marketed to treat erectile dysfunction in 2006 when a survey of 17 products revealed seven of the products as illegal drugs due to adulteration with active ingredients used in Rx ED treatments (1"The Tan Sheet" July 17, 2006, p. 4)...

You may also be interested in...



FDA Survey Of ED Supplements Shows Contamination With Viagra, Levitra

A "first-of-its-kind" FDA survey of 17 dietary supplements marketed to treat erectile dysfunction revealed that seven of the products are actually illegal drugs due to adulteration with active ingredients used in Rx ED treatments, the agency states in a July 12 release

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel